Amarin Corporation plc Sustainability Profile
Amarin Corporation plc, often referred to simply as Amarin, is a biopharmaceutical company headquartered in Ireland (IE). Founded in 1989, Amarin has established itself as a leader in the cardiovascular industry, focusing on innovative therapies for the treatment of cardiovascular diseases. The company is best known for its flagship product, Vascepa, a prescription medication that has demonstrated significant efficacy in reducing cardiovascular risk. This unique omega-3 fatty acid formulation sets Amarin apart in a competitive market, addressing unmet medical needs with a strong clinical foundation. With a robust presence in North America and Europe, Amarin continues to expand its reach and influence in the healthcare sector. The company has achieved notable milestones, including regulatory approvals and positive clinical trial results, solidifying its position as a key player in the biopharmaceutical landscape.
DitchCarbon Score
How does Amarin Corporation plc's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Amarin Corporation plc's score of 26 is lower than 56% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Amarin Corporation plc's reported carbon emissions
Amarin Corporation plc, headquartered in Ireland (IE), currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges associated with the company. This lack of data suggests that Amarin may not have established formal commitments to reduce its carbon footprint or engage in industry-standard climate initiatives such as the Science Based Targets initiative (SBTi) or the Carbon Disclosure Project (CDP). In the context of the pharmaceutical industry, where companies are increasingly focusing on sustainability and carbon reduction, Amarin's current position may reflect an opportunity for future engagement in climate commitments. As the industry moves towards greater transparency and accountability in emissions reporting, it will be essential for Amarin to consider setting measurable targets and participating in recognised climate initiatives to align with best practices and stakeholder expectations.
How Carbon Intensive is Amarin Corporation plc's Industry?
How Carbon Intensive is Amarin Corporation plc's Location?
Amarin Corporation plc's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Amarin Corporation plc has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
